☆ 4.7 Meeting Abstract

Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).

JOURNAL OF CLINICAL ONCOLOGY (2015)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 33, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/jco.2015.33.15_suppl.505

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.